AMNEAL PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $57.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $57.66M, a 157.22% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $62.26M, a 410.50% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $2.37M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $22.42M, a 273.99% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$116.89M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$83.99M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$129.99M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $57.66M 10-Q · filed 2026-08-06 | $119.92M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $62.26M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $2.37M 10-Q · filed 2025-11-06 | $24.79M derived: sum of 2 quarters · filed 2026-08-06 | $36.98M 10-Q · filed 2025-11-06 | $5.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $22.42M 10-Q · filed 2026-08-06 | $34.61M 10-Q · filed 2026-08-06 | $3.53M derived: sum of 3 quarters · filed 2026-08-06 | $3.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.20M 10-Q · filed 2026-05-07 | -$18.89M derived: sum of 2 quarters · filed 2026-05-07 | -$19.04M derived: sum of 3 quarters · filed 2026-05-07 | -$13.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$31.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$31.24M derived: sum of 2 quarters · filed 2025-11-06 | -$25.24M derived: sum of 3 quarters · filed 2025-11-06 | -$116.89M 10-K · filed 2025-02-28 |
| 2024-09-30 | -$156.00K 10-Q · filed 2025-11-06 | $5.84M derived: sum of 2 quarters · filed 2025-11-06 | -$85.81M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $5.99M 10-Q · filed 2025-08-07 | -$85.65M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$91.64M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$83.99M 10-K · filed 2025-02-28 | |||
| 2022-12-31 | -$129.99M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |